Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.38 |
| ▸ | CNR2 | P34972 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25850543 | 0.85 | CNR1 (0.44) | CNR1CNR2TRPV1 | |
| SCHEMBL26035275 | 0.84 | CNR1 (0.39) | CNR1CNR2MEN1ALDH1A1MAPT | |
| SCHEMBL24341855 | 0.81 | FAAH (0.44) | CNR1CNR2MEN1KMT2AFAAH | |
| SCHEMBL25850206 | 0.79 | FAAH (0.43) | CNR1CNR2FAAH | |
| SCHEMBL21096814 | 0.78 | FAAH (0.46) | CNR1CNR2MEN1KMT2AFAAH | |
| SCHEMBL26048828 | 0.77 | CNR1 (0.38) | CNR1CNR2TRPV1 | |
| SCHEMBL25849437 | 0.75 | FAAH (0.43) | CNR1CNR2FAAHEPHX2 | |
| SCHEMBL26034080 | 0.74 | FAAH (0.47) | CNR1CNR2MEN1KMT2AFAAH | |
| SCHEMBL25848473 | 0.74 | NOD1 (0.40) | FAAH | |
| SCHEMBL24340612 | 0.71 | FAAH (0.39) | CNR1CNR2FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | CNR1 4167/4885CNR2 4501/4885MEN1 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.